XML 32 R17.htm IDEA: XBRL DOCUMENT
v3.25.2

Net Loss per Share | 6 Months Ended
--- | ---
Jun. 30, 2025
Earnings Per Share [Abstract] |
Net Loss per Share | Net Loss per Share Basic and diluted net loss per common share attributable to common stockholders was calculated as follows:
|  | Three Months Ended June 30, |  | Six Months Ended June 30,
(in thousands, except share and per share amounts) |  | 2025 |  | 2024 |  | 2025 |  | 2024
Numerator: |  |  |  |  |  |  |  |
Net loss attributable to common stockholders |  | $ | (52,591) |  |  | $ | (55,327) |  |  | $ | (104,481) |  |  | $ | (101,088) |
Denominator: |  |  |  |  |  |  |  |
Weighted-average common shares outstanding, basic and diluted |  | 129,185,918 |  |  | 119,188,866 |  |  | 128,439,349 |  |  | 111,827,522 |
Net loss per share attributable to common stockholders, basic and diluted |  | $ | (0.41) |  |  | $ | (0.46) |  |  | $ | (0.81) |  |  | $ | (0.90) |
Diluted net loss per share available to common stockholders is computed by giving effect to all potentially dilutive common stock equivalents outstanding for the period. For purposes of this calculation, preferred stock, unvested restricted stock and stock options to purchase common stock were considered common stock equivalents but had been excluded from the calculation of diluted net loss per share available to common stockholders as their effect was anti-dilutive. In periods in which the Company reports a net loss available to common stockholders, diluted net loss per share available to common stockholders is the same as basic net loss per share available to common stockholders, since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The following common stock equivalents were excluded from the calculation of diluted net loss per share applicable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
|  | As of June 30,
|  | 2025 |  | 2024
Anti-dilutive common stock equivalents: |  |  |  |
Options to purchase common stock |  | 17,685,319 |  |  | 12,007,443 |
Unvested restricted common stock |  | 3,472,546 |  |  | 3,729,877 |
Total anti-dilutive common stock equivalents: |  | 21,157,865 |  |  | 15,737,320 |

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for earnings per share. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details
Name: | us-gaap_EarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration